Benign Prostatic Hyperplasia (BPH)

Benign prostatic hyperplasia (BPH) is a nonmalignant enlargement of the prostate. The most common clinical manifestation of BPH is lower urinary tract symptoms, including urinary frequency, urgency, nocturia, decreased and intermittent force of stream and sensation of incomplete bladder emptying. BPH is a disease of the aging male population with a dramatic increase in incidence after the age of 50 years. BPH will affect approximately 50 percent of men between the ages of 51 and 60 and up to 90 percent of men over the age of 80 (AUA 2003).

Phase 1 and Phase 2 studies in patients with BPH are underway. The Aptocine drug activator used in BPH is incorporated into a single-use, disposable Foley catheter, providing a simple, easy-to-administer outpatient treatment.

References

• American Urologic Association. AUA Guideline on the Management of Benign Prostatic Hyperplasia (Linthicum, MD, AUA: 2003).